Ballicules.com

Pegfilgrastim

NEULASTA

What it isPegylated G-CSF receptor agonist; prevention of chemotherapy-associated febrile neutropenia.

Why this oneThe pegylation is the product: self-regulating clearance by neutrophils turns daily filgrastim injections into a single next-day dose (or on-body injector).

What limits itBone pain is common; splenic rupture and acute respiratory distress are uncommon but serious. Do not administer too close to cytotoxic chemotherapy.

FDA label

FDA dosingPopulationStartTargetMax
Chemotherapy-induced febrile neutropenia (myelosuppressive chemo)adults and pediatric6 mg SC once per chemotherapy cycle (adults any weight and pediatrics ≥45 kg); weight-based if <45 kg6 mg per cycle6 mg per cycle
Hematopoietic subsyndrome of acute radiation syndromeadults and pediatric6 mg SC, two doses one week apart (adults any weight and pediatrics ≥45 kg); weight-based if <45 kgtwo 6 mg doses one week apart6 mg per dose

Renal Undefined

Hepatic Undefined

Instructions

Cautions

Adverse reactions

Pregnancy Insufficient human data; animal studies showed embryolethality/abortions in rabbits at higher doses.

Lactation No data on presence in human milk; filgrastim products are secreted poorly and not orally absorbed by neonates.

NO BOXED WARNINGS

Classes and tags

Clinical profile

Direct muscarinic antagonism0 / 4

Mechanism of action: Pegfilgrastim ballicule

Pegfilgrastim ballicule: receptor binding, kinetics and half-life diagram

Open Pegfilgrastim in the interactive console ↗